Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


HHS Advances Payment Model to Lower Drug Costs


 

In late October, the U.S. Department of Health and Human Services, through the Centers for Medicare & Medicaid Services (CMS), announced and sought input on a new "International Pricing Index" (IPI) payment model to reduce what Americans pay for prescription drugs.

Under the IPI model, described in an Advance Notice of Proposed Rulemaking (ANPRM), Medicare's payments for select physician-administered drugs would shift to a level more closely aligned with prices in other countries. Overall savings for American taxpayers and patients are projected to total $17.2 billion over five years.

"In an era where the pharmaceutical industry is pricing drugs at levels approaching a million dollars -- and jeopardizing the future of our safety net programs -- the time has come to fix the perverse incentives in the Medicare program that are fueling price increases," said CMS Administrator Seema Verma.

The move from current payment levels to payment levels based on international prices would be phased in over a five-year period, would apply to 50 percent of the country, and would cover most drugs in Medicare Part B, which includes physician-administered medicines such as infusions. The model purports to "correct existing incentives to prescribe higher-priced drugs and, for the first time, address disparities in prices between the United States and other countries." Since patient cost sharing is calculated based on Medicare's payment amount, patients should see lower costs under the model.

For the first time in Medicare, the IPI model would create a system in which private vendors procure drugs, distribute them to physicians and hospitals, and take on the responsibility of billing Medicare. The plan is that vendors would aggregate purchasing, seek volume-based discounts, and compete for providers' business, thereby creating competition where none exists today. Under the model, instead of the current percentage-based add-on payment, physicians and hospitals would receive a set payment amount for storing and handling drugs that would not be tied to drug prices to remove any financial incentive to prescribe higher-cost drugs.

AMA President Barbara L. McAneny, MD, responded to the proposed rule with the following statement: "Physicians share their patients' concerns with the high cost of prescription drugs. We appreciate that the Trump Administration is working to address this important issue. The Administration's proposal for an International Pricing Index Model for Part B drugs raises a number of questions, and we need to have a greater understanding of the potential impact of the proposal on patients, physicians, and the health care system. We look forward to working constructively with the Administration as it seeks feedback."

TAGS:

WEB:

IPI Policy Brief

Fact Sheet

Comments

 
Share:

Related Articles:


Recent Articles

AMA Supports Congress Providing Much-Needed Relief to Physicians Working Through the Pandemic

CHICAGO -- The American Medical Association (AMA) strongly supports provisions in the Continuing Resolution that will offer relief to hard-pressed physician practices. Revisions to the Medicare Accelerated and Advance Payments program (AAP) will help keep doors open during the pandemic and continue to offer patients access at this time.

Read More

AMA Releases 2021 CPT Code Set

New updates to medicine's common language reflect burden relief, COVID-19 testing and tech-enabled medical services

Read More

Council on Aging Offers Helpline, Resources for Healthcare Providers

COA offers a helpline and lifeline to providers, older adults, caregivers and family members trying to navigate services.

Read More

VUMC Launches Groundwork for Tennessee's First Federally Funded Alzheimer's Disease Research Center

Angela Jefferson, PhD, professor of Neurology and director of the Vanderbilt Memory and Alzheimer's Center, has been awarded a grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to support establishment of an NIA-funded exploratory Alzheimer's Disease Research Center (ADRC) at Vanderbilt University Medical Center (VUMC).

Read More

From Pain Management to Pandemic: The Changing Face of Sports Medicine

New norms mean new routines and standards of care on and off the field.

Read More

Kids, Classrooms and COVID-19

Risk mitigation key as kids hit the classrooms.

Read More

Meharry, Wharton Partner on Dual Degree Program

Meharry Medical College and the Wharton School at the University of Pennsylvania have partnered on a joint MD/PhD program.

Read More

Practice Management Q&A with NMGMA

NMGMA leaders answer questions about challenging practice management issues.

Read More

Physician Practice Leadership in a Post-COVID-19 Environment

COVID-19 has changed just about every aspect of daily life, including the way care is delivered. Looking toward a post-COVID landscape, practice leaders will need to reevaluate processes and assess the best way forward.

Read More

Economic Effect of COVID-19 Shutdowns & PPP Relief

A public health crisis, COVID-19 has also proven to be an economic crisis for practices and providers. For those receiving PPP relief, the path to forgiveness is coming into focus.

Read More

Email Print
 
 

 

 


Tags:
CMS, HHS, International Pricing Index, IPI, Medicare, Medicare Part B, Prescription Drugs, Seema Verma
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: